Advertisement
UK markets close in 7 hours 38 minutes

  • FTSE 100

    8,058.81
    +34.94 (+0.44%)
     

  • FTSE 250

    19,653.28
    +53.89 (+0.27%)
     

  • AIM

    751.32
    +2.14 (+0.29%)
     

  • GBP/EUR

    1.1576
    -0.0013 (-0.11%)
     

  • GBP/USD

    1.2362
    +0.0012 (+0.09%)
     

  • Bitcoin GBP

    53,554.54
    +80.95 (+0.15%)
     

  • CMC Crypto 200

    1,394.45
    -20.31 (-1.44%)
     

  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     

  • DOW

    38,239.98
    +253.58 (+0.67%)
     

  • CRUDE OIL

    82.37
    +0.47 (+0.57%)
     

  • GOLD FUTURES

    2,323.70
    -22.70 (-0.97%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • HANG SENG

    16,832.15
    +320.46 (+1.94%)
     

  • DAX

    17,981.88
    +121.08 (+0.68%)
     

  • CAC 40

    8,059.65
    +19.29 (+0.24%)
     
Money:

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

Amicus' Fabry disease drug gets European Commission approval

Reuters - UK Focus

(Adds background)

May 31 (Reuters) - Amicus Therapeutics Inc (NasdaqGM: FOLD - news) said on Tuesday the European Commission approved the use of migalastat, its experimental treatment for Fabry disease, an inherited disease that creates pain and burning in the hands and feet.

The European Medicines Agency had recommended approving migalastat in April. The Cranbury, New Jersey-based company is still seeking approval from U.S (Other OTC: UBGXF - news) . regulators.

Fabry disease is a potentially fatal disorder that affects about 1 in 40,000 to 60,000 men and occurs less frequently in women. It (Other OTC: ITGL - news) is caused by the build-up of fat-like substances, most notably in the kidneys, due to the deficiency or lack of an enzyme that metabolizes these lipids.

ADVERTISEMENT

The accumulation damages cells and can lead to kidney failure, heart attacks and strokes. It is currently treated with metoclopramide.

The U.S. Food and Drug Administration last fall asked Amicus for more comprehensive analysis of its trial data and the company put off submitting a new marketing application for the treatment. (Reporting by Noor Zainab Hussain in Bengaluru and Caroline Humer in New York; Editing by Sriraj Kalluvila and Jeffrey Benkoe)